Literature DB >> 15690146

[Carcinoma of the urinary bladder. Konservative oder operative Therapie bei PT1G3].

K Miller1, R Hautmann.   

Abstract

As no prospective randomised studies are available on therapy and outcome in T1G3 carcinoma of the urinary bladder, a decision on therapy can only be made on the basis of retrospective studies or with reference to the individual experience of a particular urologist. In this paper the advantages and disadvantages of primary cystectomy and of transurethral resection, both alone and in combination with BCG instillation, are discussed and compared.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15690146     DOI: 10.1007/s00120-005-0762-3

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  14 in total

1.  Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy?

Authors:  George N Thalmann; Regula Markwalder; Osama Shahin; Fiona C Burkhard; Werner W Hochreiter; Urs E Studer
Journal:  J Urol       Date:  2004-07       Impact factor: 7.450

2.  A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival.

Authors:  Osama Shahin; George N Thalmann; Cyrill Rentsch; L Mazzucchelli; U E Studer
Journal:  J Urol       Date:  2003-01       Impact factor: 7.450

3.  Prognostic value of p53 overexpression in T1G3 bladder tumors treated with bacillus Calmette-Guérin therapy.

Authors:  Michael Peyromaure; Sun Weibing; Philippe Sebe; Patrice Verpillat; Marianne Toublanc; Marie Christine Dauge; Laurent Boccon-Gibod; Vincent Ravery
Journal:  Urology       Date:  2002-03       Impact factor: 2.649

4.  Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.

Authors:  D L Lamm; B A Blumenstein; J D Crissman; J E Montie; J E Gottesman; B A Lowe; M F Sarosdy; R D Bohl; H B Grossman; T M Beck; J T Leimert; E D Crawford
Journal:  J Urol       Date:  2000-04       Impact factor: 7.450

5.  Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome.

Authors:  H W Herr
Journal:  Br J Urol       Date:  1997-11

6.  Intravesical Bacillus Calmette-Guerin treatment improves patient survival in T1G3 bladder tumours.

Authors:  Jean-Jacques Patard; Alejandro Rodriguez; Emmanuelle Leray; Nathalie Rioux-Leclercq; François Guillé; Bernard Lobel
Journal:  Eur Urol       Date:  2002-06       Impact factor: 20.096

7.  Radical cystectomy--often too late?

Authors:  M Stöckle; P Alken; U Engelmann; G H Jacobi; H Riedmiller; R Hohenfellner
Journal:  Eur Urol       Date:  1987       Impact factor: 20.096

8.  The ileal neobladder: complications and functional results in 363 patients after 11 years of followup.

Authors:  R E Hautmann; R de Petriconi; H W Gottfried; K Kleinschmidt; R Mattes; T Paiss
Journal:  J Urol       Date:  1999-02       Impact factor: 7.450

9.  Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells.

Authors:  Sandeep S Dave; George Wright; Bruce Tan; Andreas Rosenwald; Randy D Gascoyne; Wing C Chan; Richard I Fisher; Rita M Braziel; Lisa M Rimsza; Thomas M Grogan; Thomas P Miller; Michael LeBlanc; Timothy C Greiner; Dennis D Weisenburger; James C Lynch; Julie Vose; James O Armitage; Erlend B Smeland; Stein Kvaloy; Harald Holte; Jan Delabie; Joseph M Connors; Peter M Lansdorp; Qin Ouyang; T Andrew Lister; Andrew J Davies; Andrew J Norton; H Konrad Muller-Hermelink; German Ott; Elias Campo; Emilio Montserrat; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Liming Yang; John Powell; Hong Zhao; Neta Goldschmidt; Michael Chiorazzi; Louis M Staudt
Journal:  N Engl J Med       Date:  2004-11-18       Impact factor: 91.245

Review 10.  Host genetics and tumour metastasis.

Authors:  K W Hunter
Journal:  Br J Cancer       Date:  2004-02-23       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.